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Abstract
Background: HELLP syndrome is a combination of symptoms described as hemolysis, elevated liver enzymes and
low platelets, that complicates 0.01–0.6 % of pregnancies. HELLP syndrome has been scarcely reported associated
with partial moles, another rare complication of pregnancy. This manuscript describes the only reported case of
HELLP syndrome associated with a complete invasive hydatiform mole.
Case presentation: We report a perimenopausal patient in prolonged remission from an uncommon high-risk
invasive complete mole. The diagnosis was set in a context of early onset preeclampsia and HELLP syndrome. The
development of life-threatening complications required primary hysterectomy. Postoperative hCG quickly returned
to normal with EMA/CO multi-agent chemotherapy.
Conclusion: Our patient is in prolonged remission from a complete mole complicated with EOP and HELLP
syndrome. This exceptional case of complicated gestational trophoblastic neoplasia reflects a very rare condition in
which several risk factors for placental ischemia are associated. Emergency hysterectomy should be considered as
salvage initial treatment in such life-threatening situations.
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Background
HELLP, a syndrome characterized by hemolysis, elevated
liver enzyme levels and a low platelet count, is a very
rare and severe obstetric complication that usually presents
in the third trimester of pregnancy [1].
In perimenopausal women, spontaneous pregnancy
is rare and associated with an increased incidence of mater-
nal complications such as pregnancy-induced hypertension
and the related complications: preeclampsia and HELLP
syndrome [2].
Specifically in this age group in parallel, the risk of
gestational trophoblastic disease (GTD) has been re-
ported as high as 1 in 8 pregnancies over the age of
50 - with a higher potential for malignant transformation
[3–6]. GTD not only refers to premalignant entities such
as complete and partial hydatiform moles (HM) but also
to malignant diseases - termed gestational trophoblastic
neoplasia (GTN) - such as invasive mole, choriocarcin-
oma, placental site and epithelioid trophoblastic tumours.
Reference treatment of HM in reproductive age women is
uterine evacuation while chemotherapy is indicated to
treat FIGO low- or high-risk GTN [6]. In perimenopausal
women, a primary hysterectomy can be recommended
either as a method for uterine evacuation of HM or
as a primary treatment of non-metastatic GTN with
or without severe bleeding [5, 7].
Case presentation
A 52- year old perimenopausal caucasian woman, gravida
3 para 3, with a 10-week long vaginal bleeding, bloating,
fatigue, weight gain (>7 kg), and hypogastric mass was ad-
mitted to the local emergency room for an epigastric pain
and a mild dyspnea. She also observed breast tenderness
for the last 3 months. Her personal history included:
appendectomy, amiodarone-induced hypothyroidism,
chronic atrial fibrillation and breast abscess but not
hypertension. Her last delivery was 23 years ago and she
discontinued oral contraceptive pill at least 18 months
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back. She then observed hot flashes and menstrual
irregularity with longer menstrual cycles and her last
menses occurred 4 months ago.
A computed tomography (CT) scan of the chest,
abdomen and pelvis showed a uterine enlargement
(15 × 12 cm axial) with a heterogeneous hypodense endo-
metrium punctuated with nodular areas enhanced by io-
dinated contrast (Fig. 1a & b). Neither fetus nor adnexal
mass was detected. Diffuse bilateral pulmonary nodules
were observed (Fig. 1c). While her serum hCG level
was 0.96 × 106 IU/L, an endometrial trans-cervical biopsy
showed two non-malignant chorionic villi.
When she was referred to the regional cancer center
ten days later, she was further diagnosed with the follow-
ing signs of early onset preeclampsia (EOP): new onset
of severe hypertension (170/100 mmHg), proteinuria,
oliguria, headache, hyper reflexivity in lower limbs and
growing epigastric pain radiating to both hypochondria.
While her fundal height was measured to be 18 cm, her
laboratory tests including TBC, kidney and liver function
were initially normal except a serum hCG test rising to
1.266 × 106 IU/L. Blood pressure and diuresis were stabi-
lized after a parenteral treatment of severe hypertension
and pain. Her biological results, however, rapidly deterio-
rated with hemolytic anemia (hemoglobin 97 g/L, haptoglo-
bin <0.06 g/L), thrombocytopenia (75 G/L), and elevated
liver enzymes (ALT 120 IU/L, AST 252 IU/L). Additionally,
she developed severe proteinuria (1.85 g/24 h). Together,
she presented a complete form of HELLP syndrome.
The patient was transferred to the intensive care unit
and a salvage total abdominal hysterectomy with bilateral
salpingo-oophorectomy was immediately decided in ac-
cordance with the French Trophoblastic Disease Reference
Centre advice. Gross examination of the specimen showed
an enlarged and tensed uterine body (22 × 20 × 10 cm,
Fig. 2a) whose longitudinal incision released macroscopic
vesicles without any identifiable fetus (Fig. 2b). Histo-
logical examination further revealed a complete and
invasive hydatidiform mole (Fig. 2 c & d). Histology
was reviewed within the French network of trophoblastic
disease referent pathologists.
One week after hysterectomy, her biological results
markedly improved (hemoglobin 105 g/L, haptoglobin
2.7 g/L, platelets 311 G/L, ALT 24 IU/L, AST 23 IU/L
and hCG 31.240 × 103 IU/L.
Thoraco-abdomino-pelvic CT scan, liver MRI, brain
CT and 18 F-FDG PET/CT detected diffuse metastases
limited to the lungs (visible on chest CT scan but not by
chest-X-ray). She was thus considered to develop a post-
molar high-risk GTN with a FIGO stage/score of III:7
[8]. Therefore, an EMA-CO multi-agent chemotherapy
was initiated at day 20 post-operative, as the patient left
the intensive care unit [9]. She was subsequently regis-
tered in the national database with her informed signed
consent [10]. Complete remission of GTN was ascer-
tained by the rapid hCG regression within 10 weeks
(Fig. 3). She was administered five EMA/CO cycles with
two more consolidation courses after normalization of
serum hCG levels that were periodically followed up to
24 months [11]. A complete response was observed on
Fig. 1 Abdominopelvic contrast-enhanced CT scans showing an enlarged uterus with focal areas of hypoattenuation; a mid sagittal plane;
b transverse plan. c Axial chest CT scan (lung window) showing at least one left pulmonary metastase
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the thoracic CT four months after diagnosis. The patient
is disease-free for ten years.
Discussion
Patients in their sixth decade are not expected to be
spontaneously pregnant, and a physician may not even
think of checking hCG level when confronted with ab-
normal vaginal bleeding. Moreover low levels of hCG
production in the perimenopausal and postmenopausal
state is a normal physiologic phenomenon [12]. There-
fore, the diagnosis of pregnancy and, moreover, GTD
may be difficult.
In the particular case of our patient, we had to face an
unusual clinical presentation. While the usual presenting
symptoms of perimenopausal GTD are vaginal bleeding,
stigmata of pregnancy with nausea or vomiting [5, 13],
our patient presented with early onset preeclampsia
(EOP), a rare condition that develops during the second
Fig. 2 a Photograph of the specimen with scale (cm); b Photograph of the specimen with longitudinal incision exposing vesicles; c Low
magnification micrograph of the invasive complete hydatiform mole component (hematoxylin and eosin): two enlarged chorionic villi associated
with a trophoblastic proliferation invading the vessels and the muscular wall of the uterus (bottom left); d high magnification micrograph of a
suspected choriocarcinomatous component (hematoxylin and eosin): large syncitiotrophoblasts associated with a proliferation of atypical
intermediate cytotrophoblasts
Fig. 3 Response to treatment measured by hCG tumour marker concentration in blood
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trimester of gestation and can complicate GTD, especially
in older reproductive age women [14]. EOP is associated
with a high incidence of HELLP syndrome and a 20-fold
increase in maternal mortality [15, 16]. EOP is particularly
difficult to diagnose when preexisting disease such as
hypertension is present, especially in peri/postmenopausal
women. Other less common causes of severe hyperten-
sion, including thyrotoxicosis, pheochromocytoma and
recreational drug use, should be considered in the differ-
ential diagnosis. EOP and some glomerulopathies - pos-
sibly related to hypertension - may have similar clinical
and laboratory findings. Conversely preeclampsia itself in-
creases the risk of kidney disease later in life. The main
differential diagnoses of HELLP include thrombotic mi-
croangiopathies (thrombotic thrombocytopaenic purpura
and haemolytic uraemic syndrome (HUS) and acute fatty
liver of pregnancy.
Another atypical characteristics of the disease reported
here is the absence of described association between
HELLP syndrome and complete hydatidiform moles,
whatever the age of the patients. Only HELLP syndromes
with partial moles have been scarcely reported [17–19].
Conclusion
Our patient is in prolonged remission from a complete in-
vasive mole complicated with EOP and HELLP syndrome.
The development of such a life-threatening complication
can require emergency primary hysterectomy, which can
be recommended as the first curative approach of GTN
when childbearing considerations have been fulfilled. Rela-
tionship of this exceptional HELLP syndrome in a GTN
should be further investigated.
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